Weight-Adjusted Hydroxychloroquine and Azithromycin Boosted Survival of Ventilated COVID-19 Patients by 200 Percent: Study

By Epoch Times ——Bio and Archives--June 9, 2021

News Headlines | CFP Comments | Reader Friendly | Subscribe | Email Us

A new study has found that the use of weight-adjusted Hydroxychloroquine (HCQ) and Azithromycin (AZM) improved the survival of ventilated COVID-19 patients by nearly 200 percent. The observational study, which has not yet been peer-reviewed, was based on a re-analysis of 255 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic in the United States.-- More...

Support Canada Free Press

View Comments

Epoch Times——Bio and Archives

The Epoch Times: “A Fresh Look at Our Changing World”

The Epoch Times is a privately held news media company. The center is in New York, but our network of local reporters throughout the world uncovers stories that are authentically local, yet also globally relevant. Our independence enables us to report widely and present a diversity of opinions.

We have offices in 30 countries across five continents, and our content is published in 17 languages. We are proud to offer print and web editions in Chinese, English, German, French, Spanish, Hebrew, Russian, Japanese, Korean and Indonesian, as well as web versions in Ukrainian, Bulgarian, Romanian, Czech, Slovak, Vietnamese and Swedish.

Weight-Adjusted Hydroxychloroquine and Azithromycin Boosted Survival of Ventilated COVID-19 Patients by 200 Percent: Study

VIEW Comments